Bicyclol in the treatment of patients with chronic diffuse liver diseases
Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.Materials and methods. The study enro...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2020-10-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5830 |
| _version_ | 1797841652554924032 |
|---|---|
| author | M. V. Maevskaya V. D. Lunkov N. I. Geyvandova L. K. Palgova I. Yu. Pirogova M. K. Prashnova N. V. Marchenko E. N. Zinovieva T. A. Ilchishina V. T. Ivashkin P. V. Koroy |
| author_facet | M. V. Maevskaya V. D. Lunkov N. I. Geyvandova L. K. Palgova I. Yu. Pirogova M. K. Prashnova N. V. Marchenko E. N. Zinovieva T. A. Ilchishina V. T. Ivashkin P. V. Koroy |
| author_sort | M. V. Maevskaya |
| collection | DOAJ |
| description | Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale).Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks - 79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks - by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001).Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology. |
| first_indexed | 2024-04-09T16:34:48Z |
| format | Article |
| id | doaj.art-b81f10d8b7224f1fa30bd7ebc33da855 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:48Z |
| publishDate | 2020-10-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b81f10d8b7224f1fa30bd7ebc33da8552023-04-23T06:56:57ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902020-10-01015788910.21518/2079-701X-2020-15-78-895299Bicyclol in the treatment of patients with chronic diffuse liver diseasesM. V. Maevskaya0V. D. Lunkov1N. I. Geyvandova2L. K. Palgova3I. Yu. Pirogova4M. K. Prashnova5N. V. Marchenko6E. N. Zinovieva7T. A. Ilchishina8V. T. Ivashkin9P. V. Koroy10Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Stavropol State Medical UniversitySt Petersburg UniversityLotus Medical CenterSt Petersburg UniversityRussian Scientific Center of Radiology and Surgical Technologies named after academician A.M. GranovPolyClinic “EXPERT”SM-clinicSechenov First Moscow State Medical University (Sechenov University)Stavropol State Medical UniversityIntroduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale).Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks - 79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks - by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001).Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.https://www.med-sovet.pro/jour/article/view/5830serum transaminasessystemic and local inflammationfibrosisbicicloltreatment |
| spellingShingle | M. V. Maevskaya V. D. Lunkov N. I. Geyvandova L. K. Palgova I. Yu. Pirogova M. K. Prashnova N. V. Marchenko E. N. Zinovieva T. A. Ilchishina V. T. Ivashkin P. V. Koroy Bicyclol in the treatment of patients with chronic diffuse liver diseases Медицинский совет serum transaminases systemic and local inflammation fibrosis biciclol treatment |
| title | Bicyclol in the treatment of patients with chronic diffuse liver diseases |
| title_full | Bicyclol in the treatment of patients with chronic diffuse liver diseases |
| title_fullStr | Bicyclol in the treatment of patients with chronic diffuse liver diseases |
| title_full_unstemmed | Bicyclol in the treatment of patients with chronic diffuse liver diseases |
| title_short | Bicyclol in the treatment of patients with chronic diffuse liver diseases |
| title_sort | bicyclol in the treatment of patients with chronic diffuse liver diseases |
| topic | serum transaminases systemic and local inflammation fibrosis biciclol treatment |
| url | https://www.med-sovet.pro/jour/article/view/5830 |
| work_keys_str_mv | AT mvmaevskaya bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT vdlunkov bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT nigeyvandova bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT lkpalgova bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT iyupirogova bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT mkprashnova bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT nvmarchenko bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT enzinovieva bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT tailchishina bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT vtivashkin bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases AT pvkoroy bicyclolinthetreatmentofpatientswithchronicdiffuseliverdiseases |